Search clinical trials for: dabigatran (Pradaxa)

Total 301 results

Boehringer Ingelheim

Completed

Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

Venous Thromboembolism | Secondary Prevention

United States, Norway, Canada, Belgium, Thailand, Italy, Germany, Turkey, Austria, Hungary, Czechia, Taiwan, Israel, Brazil, Denmark, France, Lithuania, Mexico, Russian Federation, Sweden, Switzerland, Ukraine
Boehringer Ingelheim

Completed

Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.

Renal Insufficiency, Chronic

Netherlands
Korea University

Unknown

Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk

Atrial Fibrillation | Thromboembolism
Boehringer Ingelheim

Completed

Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis

Cardiovascular Diseases | Kidney Failure, Chronic

Germany
Boehringer Ingelheim

Completed

Assessment of Electrophysiological Effects of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects.

Healthy
Capital Medical University

Unknown

The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis

Cerebral Venous Thrombosis

China
Boehringer Ingelheim

Withdrawn

Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age

Venous Thromboembolism

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

Thromboembolism

Spain, Germany, India, Italy, Netherlands, Portugal, France, Poland, Russian Federation
The Affiliated Hospital Of Guizhou Medical University

Not yet recruiting

Population Pharmacokinetic Study of the Effect of Polymorphisms in the ABCB1 and CES1 Genes on the Pharmacokinetics of Dabigatran

Combined Analysis of Polymorphisms and Dabigatran Pharmacokinetic Parameters
Boehringer Ingelheim

Completed

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Arthroplasty, Replacement | Prevention of Venous Thromboembolism | Moderate Renal Impairment (CrCl 30-50 mL/Min)

Austria, Canada, Czechia, Finland, Netherlands, Sweden
Boehringer Ingelheim

Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Hepatic Insufficiency
Boehringer Ingelheim

Completed

Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention

Heart Catheterization

Netherlands
Dongyang Liu

Recruiting

Pharmacokinetic Study to Evaluate Dabigatran Etexilate in Elderly Subjects

Health, Subjective | Nonvalvular Atrial Fibrillation

China
Boehringer Ingelheim

Terminated

Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery

Venous Thromboembolism | Arthroplasty, Replacement

Austria
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Venous Thromboembolism

Italy, Thailand, Russian Federation, Canada, Lithuania, Switzerland
Boehringer Ingelheim

Completed

A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin

Atrial Fibrillation

Japan
Meshalkin Research Institute of Pathology of Circulation

Unknown

Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy (Re-Spire)

Angiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy

Russian Federation
Medical University of Gdansk
Institute of Cardiology, Warsaw, Poland; Medical University of Silesia; Pomeranian... and other collaborators

Recruiting

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI (ADONIS-PCI)

Atrial Fibrillation | Acute Coronary Syndrome | Antithrombotic Therapy | Percutaneous Coronary Interventions

Poland
Alliance Foundation Trials, LLC.
Patient-Centered Outcomes Research Institute

Completed

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer (CANVAS)

Cancer | Venous Thromboembolism | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Blood Clot

United States
Boehringer Ingelheim

Completed

PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin

Atrial Fibrillation

United States, Denmark, Sweden
Merck KGaA, Darmstadt, Germany

Completed

Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate

Healthy

Germany
Boehringer Ingelheim

Completed

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

Atrial Fibrillation

Spain, United States, United Kingdom, Canada, Germany, Italy, Japan, Belgium, Netherlands, France, Russian Federation
AstraZeneca
Eli Lilly and Company

Completed

A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

Healthy

United States
Nova Scotia Health Authority

Withdrawn

Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy

Venous Thromboses
Boehringer Ingelheim

Completed

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects

Healthy

Japan
Merck Sharp & Dohme LLC

Completed

A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)

Thrombosis
University of Southern Denmark

Completed

The Effect of Dicloxacillin on Oral Absorption of Drugs

Healthy Volunteers | Drug-drug Interaction

Denmark
University of Roma La Sapienza

Recruiting

Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk Patients (INTERMITTENT)

Atrial Fibrillation | Ischemic Heart Disease

Italy
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood

Healthy

Germany
IHF GmbH - Institut für Herzinfarktforschung
OrbusNeich

Withdrawn

COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials (COSTA)

Coronary Disease | Stable Angina | Unstable Angina | STEMI | NSTEMI

Germany
Pfizer

Completed

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

Healthy Participants

United States
Zuyderland Medisch Centrum
Boehringer Ingelheim

Recruiting

Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI (RE-DUAL PCI)

Myocardial Infarction | Myocardial Ischemia | Coronary Artery Disease | Atrial Fibrillation

Netherlands
Boehringer Ingelheim

Completed

Investigation of the Impact of Concomitant Use of Multiple Doses of Clopidogrel With Multiple Doses of Dabigatran Etexilate on the Pharmacokinetic and Pharmacodynamic Parameters in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery

Thromboembolism | Arthroplasty, Replacement, Hip

Australia, Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, South Africa, Spain, Sweden
Boehringer Ingelheim

Completed

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

Venous Thromboembolism

United States, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, Germany, Hungary, India, Italy, Netherlands, New Zealand, Norway, Poland, South Africa, Spain, Sweden
Pfizer

Withdrawn

NOAC Portuguese Real World Study

Stroke | Systemic Embolism | Major Bleeding
The First Affiliated Hospital with Nanjing Medical...

Unknown

The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients

Atrial Fibrillation

China
Boehringer Ingelheim

Completed

RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery

Thromboembolism | Arthroplasty, Replacement, Knee

Australia, Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Poland, South Africa, Spain, Sweden
Boehringer Ingelheim

Completed

Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)

Venous Thromboembolism

United States, Spain, Norway, Canada, Belgium, Thailand, Germany, Turkey, Austria, Hungary, Czechia, Taiwan, Israel, Brazil, Denmark, Italy, Lithuania, Russian Federation, Sweden, Switzerland, Ukraine, Mexico, Greece, Argentina, Finland, ...
Asan Medical Center
Boehringer Ingelheim

Completed

Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease (DECISIVE)

Atrial Fibrillation | Valve Heart Disease

Korea, Republic of
Pfizer

Completed

Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf) (SPAF)

Atrial Fibrillation

Spain
Boehringer Ingelheim

Completed

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Stroke | Secondary Prevention

Korea, Republic of, United States, Spain, Canada, Germany, Taiwan, Belgium, Australia, Hong Kong, India, Singapore, Thailand, Greece, Italy, Japan, China, Turkey, Russian Federation, Serbia, Switzerland, Israel, South Africa, Malaysia, Fran... and more
Boehringer Ingelheim

Completed

Relative Bioavailability and Pharmacodynamics of Dabigatran With Enoxaparin in Healthy Male and Female Volunteers

Healthy
Huons Co., Ltd.

Unknown

Clinical Trial to Assess the Safety and Pharmacokinetics of RDG-17012 Capsule and Pradaxa® Capsule in Healthy Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE) (RE-COVER II)

Thromboembolism

United States, Australia, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, France, Hungary, India, Israel, Italy, Korea, Republic of, Malaysia, Netherlands, New Zealand, Norway, Philippines, Poland, Russian Federation, Si... and more
Pfizer

Completed

A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France (SIFNOS)

Atrial Fibrillation

France
Bristol-Myers Squibb

Completed

Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients

Atrial Fibrillation
Bristol-Myers Squibb

Completed

Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S

Atrial Fibrillation

3

Subscribe